Vaccine for atherosclerosis

PK Shah, KY Chyu, PC Dimayuga, J Nilsson - Journal of the American …, 2014 - jacc.org
Atherosclerosis is an immune-mediated inflammatory disease of the arterial wall, with both
the innate and adaptive immune systems responding to many endogenous and exogenous …

Influence of intimal Chlamydophila pneumoniae persistence on cardiovascular complications after coronary intervention

I Tuleta, D Reek, P Braun, G Bauriedel, G Nickenig… - Infection, 2015 - Springer
Purpose Chlamydophila pneumoniae has been implicated in atherosclerosis/restenosis;
however, clear evidence is missing. Therefore, the aim of our study was to examine the …

Rapamycin can Inhibit the Development of Chlamydia pneumoniae, which Might Partly Contribute to the Prevention of In-stent Restenosis

Y Yan, S Silvennoinen-Kassinen, M Leinonen… - … drugs and therapy, 2010 - Springer
Background Rapamycin, an immunosuppressive and antiproliferative drug, is used to
prevent neointima formation to reduce the risk of in-stent restenosis with rapamycin eluting …

[PDF][PDF] RĪGAS STRADIŅA UNIVERSITĀTE NEIROLOĢIJAS UN NEIROĶIRURĢIJAS KATEDRA

PUNCS AR - rsu.lv
Jebkuru slimību vislabāk raksturo trīs rādītāji, kas atspoguļo slimības būtībusaslimstības
biežums, invaliditāte un mirstība. Cerebrālam infarktam šie rādītāji turpina saglabāties …

The antichlamydial effects of drugs used in cardiovascular diseases

Y Yan - 2009 - oulurepo.oulu.fi
Chronic Chlamydia pneumoniae infections have been associated with cardiovascular
diseases (CVD), but the treatment is difficult. Some drugs used for CVD have been found to …

Chronic Infections as Risk Factors for Atherothrombosis

PK Shah, B Cercek - Risk Factors in Coronary Artery Disease, 2006 - taylorfrancis.com
Chronic infections as potential culprits in the vascular inflammatory response have received
renewed interest since the critical role of inflammation in the evolution, progression, and …